IUPHAR-review: The Integration of Classic Psychedelics into Current Substance Use Disorder Treatment Models.

Substance use disorders (SUDs) have an enormous impact on public health. With classic psychedelic-assisted therapies showing initial promise in treating multiple SUDs, it is possible that these treatments will become legally available options for patients with SUDs in the future. This article highlights how classic psychedelic-assisted therapies might be integrated into current clinical practice. We first describe contemporary evidence-based treatments for SUDs and highlight how classic psychedelic-assisted therapies might fit within each treatment. We suggest that classic psychedelic-assisted therapies can be integrated into most mainstream evidence-based SUD treatments that are currently used in clinical settings, indicating broad compatibility of classic psychedelics with contemporary SUD treatment paradigms.

Informations de copyright

Copyright © 2023. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Declaration of Competing Interests AGR is a paid scientific advisor to NeonMind Biosciences, InnerWell, and ETHA Natural Botanicals. AGR received research funding from MicroDoz Therapy Inc., Mydecine Innovations Group Inc., Unlimited Sciences, the Council on Spiritual Practices, the Heffter Research Institute, and NIH. MWJ has been in paid advisory relationships with the following organizations regarding the medical development of psychedelics and related compounds: AJNA Labs LLC, AWAKN Life Sciences Inc., Beckley Psychedelic Ltd., Entheogen Biomedical Corp., Field Trip Psychedelics Inc., Mind Medicine Inc., Silo Pharma Inc., and Otsuka Pharmaceutical Development & Commercialization Inc. DBY, MEY, ML, JR, SN, MWJ, and AGR receives research funding support through the Johns Hopkins Center for Psychedelic and Consciousness Research provided by Tim Ferriss, Matt Mullenweg, Blake Mycoskie, Craig Nerenberg, and the Steven and Alexandra Cohen Foundation.